These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

712 related articles for article (PubMed ID: 22728934)

  • 1. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality.
    Shalhoub V; Shatzen EM; Ward SC; Davis J; Stevens J; Bi V; Renshaw L; Hawkins N; Wang W; Chen C; Tsai MM; Cattley RC; Wronski TJ; Xia X; Li X; Henley C; Eschenberg M; Richards WG
    J Clin Invest; 2012 Jul; 122(7):2543-53. PubMed ID: 22728934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
    Meng Y; Zhang H; Li Y; Li Q; Zuo L
    Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of tubular reabsorption of phosphate as a surrogate marker for phosphate regulation in chronic kidney disease.
    Hong YA; Lim JH; Kim MY; Kim Y; Yang KS; Chung BH; Chung S; Choi BS; Yang CW; Kim YS; Chang YS; Park CW
    Clin Exp Nephrol; 2015 Apr; 19(2):208-15. PubMed ID: 24682550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crosstalk between kidney and bone: insights from CKD-MBD.
    Suzuki K; Soeda K; Komaba H
    J Bone Miner Metab; 2024 Jul; 42(4):463-469. PubMed ID: 39060498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
    Koizumi M; Komaba H; Fukagawa M
    Contrib Nephrol; 2013; 180():110-23. PubMed ID: 23652554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease.
    Williams MJ; Sugatani T; Agapova OA; Fang Y; Gaut JP; Faugere MC; Malluche HH; Hruska KA
    Kidney Int; 2018 Jan; 93(1):147-158. PubMed ID: 28843411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteo-renal regulation of systemic phosphate metabolism.
    Razzaque MS
    IUBMB Life; 2011 Apr; 63(4):240-7. PubMed ID: 21438115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
    Yin C; Cheng C; Wang J; Zhang L; Purrunsing Y; Yang G; Zeng M; Huang H; Ren W; Ye Y; Ma H; Xing C; Wang N
    Clin Nephrol; 2020 Feb; 93(2):65-76. PubMed ID: 31793871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of Ronghuang Granule on serum FGF23, FGFRs and Klotho in non-dialysis patients with CKD-MBD and kidney deficiency and damp-heat syndrome].
    Hu S; Wang D; Zhang R; Cao Y; Jin H; Mao Y; Wei L; Ren K; Zhang X; Wang Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2018 Dec; 38(12):1427-1432. PubMed ID: 30613009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic kidney disease: mineral and bone disorder in children.
    Wesseling-Perry K; Salusky IB
    Semin Nephrol; 2013 Mar; 33(2):169-79. PubMed ID: 23465503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease.
    Stubbs JR; He N; Idiculla A; Gillihan R; Liu S; David V; Hong Y; Quarles LD
    J Bone Miner Res; 2012 Jan; 27(1):38-46. PubMed ID: 22031097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD.
    Clinkenbeard EL; Noonan ML; Thomas JC; Ni P; Hum JM; Aref M; Swallow EA; Moe SM; Allen MR; White KE
    JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGF23 and the PTH response to paricalcitol in chronic kidney disease.
    D'Arrigo G; Pizzini P; Cutrupi S; Tripepi R; Tripepi G; Mallamaci F; Zoccali C
    Eur J Clin Invest; 2020 Feb; 50(2):e13196. PubMed ID: 31863599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-serum phosphate and parathyroid hormone distinctly regulate bone loss and vascular calcification in experimental chronic kidney disease.
    Carrillo-López N; Panizo S; Alonso-Montes C; Martínez-Arias L; Avello N; Sosa P; Dusso AS; Cannata-Andía JB; Naves-Díaz M
    Nephrol Dial Transplant; 2019 Jun; 34(6):934-941. PubMed ID: 30189026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.
    Isakova T; Wahl P; Vargas GS; Gutiérrez OM; Scialla J; Xie H; Appleby D; Nessel L; Bellovich K; Chen J; Hamm L; Gadegbeku C; Horwitz E; Townsend RR; Anderson CA; Lash JP; Hsu CY; Leonard MB; Wolf M
    Kidney Int; 2011 Jun; 79(12):1370-8. PubMed ID: 21389978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant FGF23 prevents the progression of chronic kidney disease but aggravates renal osteodystrophy in uremic rats.
    Kusano K; Saito H; Segawa H; Fukushima N; Miyamoto K
    J Nutr Sci Vitaminol (Tokyo); 2009 Apr; 55(2):99-105. PubMed ID: 19436134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FGF23 neutralization improves bone quality and osseointegration of titanium implants in chronic kidney disease mice.
    Sun N; Guo Y; Liu W; Densmore M; Shalhoub V; Erben RG; Ye L; Lanske B; Yuan Q
    Sci Rep; 2015 Feb; 5():8304. PubMed ID: 25665715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Importance of Phosphate Control in Chronic Kidney Disease.
    Tsuchiya K; Akihisa T
    Nutrients; 2021 May; 13(5):. PubMed ID: 34069053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic Kidney Disease-Mineral Bone Disorder in Korean Patients: a Report from the KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD).
    Kim CS; Bae EH; Ma SK; Han SH; Lee KB; Lee J; Oh KH; Chae DW; Kim SW;
    J Korean Med Sci; 2017 Feb; 32(2):240-248. PubMed ID: 28049234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct inhibition of osteoblastic Wnt pathway by fibroblast growth factor 23 contributes to bone loss in chronic kidney disease.
    Carrillo-López N; Panizo S; Alonso-Montes C; Román-García P; Rodríguez I; Martínez-Salgado C; Dusso AS; Naves M; Cannata-Andía JB
    Kidney Int; 2016 Jul; 90(1):77-89. PubMed ID: 27165819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.